Spirobisnaphthalenes from Fungi and their Biological Activities

L. Zhou*, J. Zhao, T. Shan, X. Cai and Y. Peng*

Department of Plant Pathology, College of Agronomy and Biotechnology, China Agricultural University, Beijing 100193, China

Abstract: Spirobisnaphthalenes have a unique structural feature involving two or three oxygen atoms acting as bridges connecting two original naphthalene subunits. Most of these metabolites isolated from fungi exhibit significant antifungal, antibacterial and cytotoxic properties to show great potential applications in medicine and agriculture. This review focuses on their structural characters and biological activities, as well as their structure-activity relationship, mechanism of action, synthesis and biosynthesis.

Keywords: Spirobisnaphthalenes, spiroxin, preussomerin, deoxypreussomerin, fungi, biological activities.

INTRODUCTION

 Spirobisnaphthalenes (also called bisnaphthospiroketals) belong to a relatively new and rare family of bioactive natural products based on a 1,8-dihydroxynaphthalene derived spiroketal unit linked to a second, oxidized naphthalene moiety [1-3]. Ogish *et al*. first isolated a spirobisnaphthalene named MK 3018 (**28**) from cultures of the fungus *Tetraploa aristata* in 1989 [4]. After that, more and more spirobisnaphthalenes have been isolated from fungi especially for which growing under extreme conditions (e.g. endophytic fungi, freshwater aquatic fungi, and marine fungi). Spirobisnaphthalenes have received a particular attention as their biosynthesis is considered to help these fungi survive from the diverse environmental conditions [5-8].

 Spirobisnaphthalenes exhibit an elaborate range of hydroxylation, oxidation, and unsaturation patterns. They possess a wide range of biological properties, including antibacterial [9], antifungal [10], algicidal [2], herbicidal [9], antiplasmodial [11], nematicidal [12], antileishmanial [13], cytotoxic [11] and anti-tumor activities [14]. Some of these compounds have been identified as novel inhibitors of rasfarnesyltransferase [15], DNA gyrase [16], topoisomerase II [17] and thioredoxin-thioredoxin reductase [18], and thus are of interest in terms of their potential in cancer chemotherapy.

 On the basis of the structural skeletons, spirobisnaphthalenes can be divided into three types namely spiroxin-, preussomerin- and deoxypreussomerin-type. This review mainly deals with the structural types of spirobisnaphthalenes as well as their biological activities. In addition, structure-activity relationship, mechanism of action, biosynthesis and synthesis, interaction between plants and fungi, as well as the potential applications of these compounds will also be discussed. This report concentrates on work that appeared in the literature from 1989 to December 2009.

1. SPIROXIN-TYPE SPIROBISNAPHTHALENES AND BIOACTIVITIES

 The structures of the spiroxins are described as two partially saturated naphthalene rings joined together by two oxygen bridges and one carbon-carbon bridge. The saturated portion of each naphthalene ring is fused with an epoxide resulting in an unusual octacyclic ring system [14]. There was only five spiroxin-type spirobisnaphthalenes, that were spiroxins A (**2**), B (**3**), C (**1**), D (**4**) and E (**5**), isolated from an unidentified marine-derived fungus LL-37H248 from a soft orange coral collected from the waters of Dixon Bay, Vancouver Island, Canada (Fig. (**1**), Table **1**). Of them, spiroxin A (**2**) showed anti-tumor activity in nude mice against ovarian carcinoma. In evaluating its probable mechanism of action, it was observed that in the presence of either dithiothreitol or 2-mercaptoethanol, spiroxin A (**2**) caused a concentration-dependent nicking of pBR322 DNA, indicating that the compound partly exerted its cytotoxic effect through a single-stranded DNA cleavage. Cytotoxicity of quinones has been attributed to DNA modification, alkylation of essential protein thiol groups, oxidation of essential protein thiol groups by superoxide radicals or a combination of these mechanisms. The oxidation state of the spiroketal carbon, a masked ketone, could allow the spiroxins to behave chemically as quinone epoxides, possibly causing DNA cleavage under reducing conditions *via* an oxidative stress mechanism involving the formation of thiol conjugates [14]. Among these five spiroxins, only spiroxin A (**2**) was evaluated for its bioactivities as it was the major component produced in culture, other spiroxins should also be screened in detail on their antimicrobial and anti-tumor activity by focusing on their structure-activity relationships.

2. PREUSSOMERIN-TYPE SPIROBISNAPHTHALE-NES AND BIOACTIVITIES

 The preussomerins are a class of spirobisnaphthalenes which were first isolated as antifungal agents from the coprophilous fungus *Preussi isomera* [1,10]. These compounds are comprised of two unsaturated decalin units connected *via* three oxygen bridges through two spiroketal carbons located in each of the upper and lower decalin units. Twenty

1389-5575/10 \$55.00+.00 © 2010 Bentham Science Publishers Ltd.

^{*}Address correspondence to these authors at the Department of Plant Pathology, College of Agronomy and Biotechnology, China Agricultural University, Beijing 100193, China; Tel: +86 10 62731199;

Fax: +86 10 62731062; E-mail: pengyl@cau.edu.cn, lgzhou@cau.edu.cn

Fig. (1). Structures of spiroxin-type spirobisnaphthalenes (**1**-**5**).

preussomerins, which demonstrated multi-biological activities (Fig. (**2**), Table **2**), have been isolated from the fungi so far.

 Ras (p21) farnesyl-protein transferase (FPTase) is a hetero-dimeric enzyme that catalyses the transfer of the farnesyl group from farnesyl pyrophosphate (FPP) onto cysteine 186 at the C-terminus of the Ras peptide. This enzyme plays a critical role in the post-translational modification of a huge range of different proteins involved in intracellular signaling [19,20]. There is now evidence that FPTase inhibitors have been developed as potential anti-tumor therapeutic drugs, blocking the growth of human cancers. It is considered to be the first step toward the development of an effective agent for treatment of cancers, particularly those with mutated *ras* gene such as colon and pancreatic carcinomas [21]. Four preussomerins (**7**, **9**, **19**, **21**), isolated from an unidentified fungus MF5916, acted as novel inhibitors of FPTase with the median inhibitory concentration (IC_{50}) values range of 1.2-17 μM. Preussomerins G (**9**) and D (**7**), which contained a conjugated ketone in the lower half of the molecule, exhibited more active than preussomerins H (**19**) and I (**21**), which were reduced product and Michael adduct, respectively. This characteristic seems to be critical for the activity and may serve as a Michael acceptor for nucleophilic Ras-CVLS. It is of interest in terms of the potential of preussomerins in cancer chemotherapy though the accurate mechanism of inhibition is not clear [15].

Similarly, three preussomerins EG_1 (10), EG_2 (24) and EG3 (**25**) from the endophytic fungus *Edenia gomezpompae* derived from the leaves of *Callicarpa acuminata* (Verbenaceae) collected from the ecological reserve El Eden, Quintana Roo, Mexico [22]. Of them, preussomerin $EG₁$ (10) displayed the strongest antifungal activity on almost all the tested fungi. The structure-activity relationship reveals that the presence of the C-2', C-3' double bond is possibly responsible for the higher bioactivity of preussomerin EG_1 (10). Preussomerin $EG₁$ (10) was also isolated from the Panamanian endophytic fungus *Edenia* sp. which caused significant inhibition of the growth of *Leishmania donovani* in the amastigote form with the IC_{50} value of 0.12 μ M [13].

 Tuberculosis and malaria are by far the most serious of the world's deadly diseases, and the search for new drug leads is an urgent need due to the emergence of drugresistant strains of both mycobacteria and parasites. Preussomerins E (**8**), F (**13**), G (**9**), H (**19**) and I (**21**) along with 3'-demethylpreussomerin I (**20**) were isolated from a lichen fungus *Microsphaeropsis* sp. BCC 3050 to show the moderate antimycobacterial activity on *Mycobacterium tuberculosis* H37Ra, antiplasmodial activity on *Plasmodium falciparum*, and significant cytotoxicity against KB, BC-1 and vero cell lines [11].

 Six preussomerins (**7**, **12**, **14**-**17**) from the freshwater fungus YMF 1.01029 were screened to show moderate nematicidal activities with the IC_{50} values between 100 and

Fig. (2). Structures of preussomerin-type spirobisnaphthalenes (**6**-**25**).

200 μg/mL at the 24 h time point against *Bursaphelenchus xylophilus*, a plant-parasitic and fungal-feeding nematode that caused great losses to pine forests, especially in several Asian countries. Among them, preussomerin D (**7**) was the most potent [12]. Furthermore, in the standard disk assay at 50 μg/disk, preussomerin D (7) was found to be active against some fungi (*Bipolaris maydis*, *Cochliobolus sativus*, *Fusarium verticillioides*) and bacteria (*Bacillus subtilis*, *Bacillus laterosporus*, *Staphylococcus aureus*) [23].

3. DEOXYPREUSSOMERIN-TYPE SPIROBISNAPH-THALENES AND BIOACTIVITIES

 The deoxypreussomerins are comprised of two unsaturated decalin units connected *via* two oxygen bridges through one spiroketal carbon located in one of the decalin units. About 56 deoxypreussomerins have been isolated from the fungi so far with their multi-biological activities (Fig. (**3**), Table **3**).

 Four antileishmanial deoxypreussomerins, palmarumycin CP_2 (**30**), palmarumycin CP_{17} (**31**), palmarumycin CP_{18} (**37**) and CJ-12,371 (**33**) were isolated from the Panamanian endodphytic fungus *Edenia* sp. which caused significant inhibition of the growth of *Leishmania donovani* in the amastigote form with the IC_{50} values range of 0.62-8.40 μ M [13].

 Two deoxypreussomerins CJ-12,371 (**33**) and CJ-12,372 (**34**) from the fermentation broth of an unidentified fungus N983-46 were screened to inhibit both DNA supercoiling and relaxation mediated by *Escherichia coli* DNA gyrase. Both compounds had antibacterial activity against several species of Gram-positive pathogenic bacteria, including ciprofloxacin-resistant and susceptible *Staphylcoccus aureus*, *Staphylococcus epidermidis*, *Streptococcus pyogenes*,

Table 2. Preussomerin-Type Spirobisnaphthalenes and their Biological Activities

-
- Cladospirone E (64) Palmarumycin C₉ (65) Diepoxine σ (66) Diepoxine α (67) Cladospirone D (68) Sch 49210 (69)

(Fig. 3). Contd…..

Palmarumycin C₁₆ (78) Palmarumycin CP₃ (79) Palmarumycin CP_{4a} (80) Palmarumycin CP₅ (81)

Fig. (3). Structures of deoxypreussomerin-type spirobisnaphthalenes (**26**-**81**).

agalactiae, and *Enterococcus faecalis* with minimum inhibitory concentrations (MICs) ranging from 25 to 100 μg/mL [16].

 Deoxypreussomerins A (**50**) and B (**30**) were isolated from an unidentified fungus MF5916, with modest inhibitory activity on farnesyl-protein transferase (FPTase) with the IC₅₀ values of 10 and 12 μM, respectively [15].

 Eighteen deoxypreussomerins from the endophytic fungus *Coniothyrium palmarum* derived from *Lamium purpureum* (Labiatae) were tested for antibacterial, antifungal and algicidal activity. Palmarumycins C_2 (50), C_{12} (57) and CP3 (**79**) were considerably more active than others. An oxygen function at C-8 seems to increase the general biological activity [9,27].

 The cytosolic thioredoxin redox system composed of thioredoxin-1 and the NADPH-dependent thioredoxin reductase-1 reductase is an important regulator of cell growth and survival. As thioredoxin-1 is usually overexpressed in many human tumors where it is associated with increased cell proliferation, decreased apoptosis, and decreased patient survival, thioredoxin reductase-1 should provide a target to inhibit the activity of the overexpressed thioredoxin-1 for the development of novel anti-tumor agents. It was found that palmarumycin CP_1 (26) was a potent inhibitor of thioredoxin reductase-1 [31]. A water-soluble prodrug PX-916 of a palmarumycin CP_1 analogue was developed to rapidly release the parent compound either at physiologic pH or in plasma, but was stable in acid pH, allowing its i.v. administration [31]. Diepoxine σ (also named Sch 49209, 66) was isolated from three fungal strains which were *Nattrassia mangiferae*, *Coniothyrium palmarum* and an unidentified fungus LL- 07F275. It showed multi-biological activities such as inhibitory activity on thioredoxin-thioredoxin reductase system, antifungal and anti-tumor activities [17,28-30].

Diepoxine ζ (also named Sch 53514, palmarumycin C₁₃ and cladospirone bisepoxide, **72**) was also isolated from some fungi which were *Cladosporium chlorocephalum*, *Nattrassia mangiferae*, and two unidentified fungal strains LL-07F275 and F-24'707. It showed antifungal, antibacterial and herbicidal activities as well as inhibitory activity on phospholipase D (PLD) [9,28,32-35].

 A series of deoxypreussomerins were isolated from the fermentation broth of the fungi *Nattrassia mangiferae* and an unidentified fungus [17,29,32,36,37]. Of them, Sch 49209 (**66**), Sch 49210 (**69**), Sch 50673 (**71**), Sch 50676 (**56**), Sch 53514 (**72**) and Sch 53516 (**73**) revealed potent inhibitory activity against the invasion of HT1080 human fibrosarcoma cells through a matrigel membrane in the anti-tumor invasion chamber assay. Sch 49210 (**69**), Sch 49211 (**61**), Sch 49212 (**62**), Sch 53514 (**72**), Sch 53516 (**73**), Sch 53823 (**54**) and Sch 53825 (**58**) also exhibited potent inhibitory activity in phospholipase D (PLD) assay [17,29,32,36,37].

4. BIOSYNTHESIS

 The biosynthesis investigation of spirobisnaphthalenes has been partially clarified. Biosynthesis of cladospirone bisepoxide (72) was studied by feeding ¹³C-labeled acetate to growing cultures of the fungus *Sphaeropsidales* sp. (strain F-24'707) [47]. The results indicated that both naphthalene moieties derived from the same pentaketide precursor *via* a fungal polyketide synthase (PKS). Further modifications and incorporation of oxygen from air *via* postulated monooxygenase led to cladospirone bisepoxide (**72**). Otherwise, the

Table 3. Deoxypreussomerin-Type Spirobisnaphthalenes and Their Biological Activities

(Table 3). Contd…..

Fig. (4). Proposed biosynthesis pathway of cladospirone bisepoxide (**72**) in the fungus *Sphaeropsidales* sp. (strain F-24'707) [47]. PKS: polyketide synthase; – H2O: dehydratase reactioin; [H]: reduction reaction; [O]: oxygenation reaction; **82**: 1,3,6,8-tetrahydroxynaphthalene; **83**: scytalone; **84**: 1,3,6-trihydroxynaphthalene; **85**: vermelone; **86**: 1,8-dihydroxynaphthalene (DHN).

inhibition of the biosynthesis after addition of tricyclazole confirmed that possible precursors could derive from the 1,8 dihydroxynaphthalene (DHN, **86**) biosynthesis as proposed by Krohn *et al*. [9]. The proposed intermediates of the cladospirone bisepoxide biosynthesis are outlined in Fig. (**4**).

 Van der Sar *et al*. studied the biosynthesis of *spiro*mamakone A (**87**), a potently cytotoxic and antimicrobial compound from an unidentified endophytic fungus isolated from the New Zealand native tree *Knightia excelsa* (Proteaceae), that confirmed the polyketide originating from palmarumycin CP_1 (26) belonging to the spirobisnaphthalene class [48]. The proposed biosynthesis pathway is shown in Fig. (5) . The biosynthesis route before palmarumycin $CP₁$ (26) was the same as that in Fig. (4). Palmarumycin CP_1 (26) was oxidized by rearrangement of the coupled moiety to a dihydroxynaphthyl epoxide intermediate (**88**). After oxidative cleavage, decarboxylation and deprotonation steps, a symmetric enedione carbanion (**89**) was formed. In a Knoevenagel-type reaction this stabilized carbanion intermediate could attack the aldehyde to generate *spiro*-mamakone A (**87**). Furthermore, Bode and Zeeck used UV mutagenesis and enzyme inhibitors as tools to elucidate the late biosynthesis of the spirobisnaphthalenes in detail [49].

 Krohn and coworkers proposed a biosynthesis of palmarumycin CP1 (**26**) based on a 1,8-dihydroxynaphthalene or suitable phenolic derivative precursor [9]. According to their hypothesis, coupling could occur *via* a phenol oxidation as often encountered in polyketide biosynthesis, and the chlorinated palmarumycins could be derived from addition of chloride ions to epoxides. In order to prove this mechanism, palmarumycin C_9 (65) was treated with methanolic hydrochloric acid (Fig. (**6**)). As expected, formation of chlorinated palmarumycin C_4 (34) from palmarumycin C_9 (65) could be successfully detected by TLC.

5. SYNTHESIS AND ABSOLUTE STEREOCHEMIS-TRY

 The unique skeleton and various biological activities of spirobisnaphthalenes have been attracting the interests of synthetic chemists, and synthesis of this class of compounds has recently been appeared in the literature [18,50-72]. The synthesis of preussomerin G (**9**), preussomerin F (**13**), preus-

Fig. (5). Proposed biosynthesis pathway of *spiro*-mamakone A (**87**) [48].

somerin K (**20**), preussomerin L (**22**), preussomerin I (**24**), palmarumycin CP₁ (25), palmarumycin CP₂ (29), CJ-12,371 (32), deoxypeussomerin A (49), palmarumycin C_{11} (53), diepoxin σ (65) and their analogues have been reported since 1997 [18,50-72]. The absolute configurations of the palmarumycins CP₃ (79), C₂ (50), C₉ (65), C₁₀ (70) and C₁₂ (57) along with spiroxin A (**2**) were assigned with the circular dichroism (CD) spectra in detail [73-75].

Fig. (6). Transformation of chlorinated palmarumycin C_4 (34) from palmarumycin C₉ (65).

6. SPIROBISNAPHTHALENES FROM PLANTS

 Three deoxypreussomerin-type spirobisnaphthalenes, palmarumycins CP_1 (26), JC1 (54) and JC2 (90) were isolated from stems of *Jatropha curcas* (Euphorbiaceae) [76]. Both palmarumycins JC1 and JC2 showed their antibacterial activity on *Staphylococcus aureus* [76], and palmarumycin JC2 was further screened to exhibit antimycobacterial, antimalarial, antifungal, and cytotoxic activities [78]. Bipendensin (or called palmarumycin CP_1 , 26) was obtained from the sapwood of the African tree *Afzelia bipendensis* (Caesalpiniaceae) in 1993 [77]. Palmarumycins JC1 and JC2 were also isolated from fruits of *Diospyros ehretioides* (Ebenaceae) [78]. It is worth noticing that palmarumycin

JC2 (**90**) has not been isolated from the fungal samples (Fig. (**7**)).

Fig. (7). Structure of palmarumycin JC2 (**90**).

 Up to now, spirobisnaphthalenes have been isolated from the three different plant families i.e. Caesalpiniaceae (*Afzelia bipendensis*), Ebenaceae (*Diospyros ehretioides*) and Euphorbiaceae (*Jatropha curcas*). This is rather unusual from the chemotaxonomic point of view, while certain secondary metabolites could be employed as chemotaxonomic markers in particular plant genera [79-82]. It was proposed that the isolated spirobisnaphthalenes were not as the plant constituents, but they might be from the endophytic fungi present in the host plants. These findings suggested a new approach for searching new fungal metabolites on plant materials that may be deliberately infected by fungi, or on those with the associated endophytic fungi.

7. SPIROBISNAPHTHALENE PRODUCTION IN MY-CELIAL SUSPENTION

 Some spirobisnaphthalenes such as spiroxins A (**2**), B (**3**), C (**1**), D (**4**) and E (**5**) are easily excreted into liquid medium from the fungal cells in suspension culture by treatment of macroporous resin. Cultivation of the fungus LL-37H248 in potato dextrose broth containing suspended macroporous resin HP20 yielded high titers of spiroxins. Production rates were approximately 35-fold greater in the presence of HP20 than in fermentations without the resin [14].

8. CLOSING REMARKS

 In the past decades, about 81 spirobisnaphthalenes have been reported from at least 15 known fungal species and 9 un-identified fungal strains. This growing family of spirobisnaphthalenes exhibited a variety of biological activities especially for the cytotoxicity, inhibition of farnesyl-protein transferase and thioredoxin reductase-1 [83-85]. Research to date indicates that further studies on the biosynthetic pathway, metabolic regulation, structure-activity relationship, mechanism of action, physiological and ecological roles of the spirobisnaphthalenes in fungi as well as their practical applications in medicine and agriculture may be confidently expected.

ACKNOWLEDGEMENTS

 This work was co-financed by the grants from the National Basic Research Program of China (2006CB101901), the National Natural Science Foundation of China (30871662), and the Natural Science Foundation of Beijing (6092015).

REFRENCES

- [1] Weber, H.A.; Gloer, J.B. The preussomerins: novel antifungal metabolites from the coprophilous fungus *Preussia isomera* Cain. *J. Org. Chem.*, **1991**, *56*, 4355-4360.
- [2] Bode, H.B.; Walker, M.; Zeeck, A. Secondary metabolites by chemical screening, 41. Structure and biosynthesis of mutolide, a novel macrolide from a UV mutant of the fungus F-249707. *Eur. J. Org. Chem.*, **2000**, 1451-1456.
- [3] Krohn, K. Natural products derived from naphthalenoid precursors by oxidative dimerization. *Prog. Chem. Org. Nat. Prod.*, **2003**, *85*, 1-49.
- [4] Ogishi, H.; Chiba, N.; Mikawa, T.; Sasaki, T.; Miyaji, S.; Sezaki, M. Antibiotic MK3018 manufacture with *Tetraploa*. *Jpn. Pat.*, **1989**, *JP 01294686 A*.
- [5] Schulz, B.; Boyle, C.; Draeger, S.; Roemmert, A.-K.; Krohn, K. Endophytic fungi: a source of novel biologically active secondary metabolites. *Mycol. Res.*, **2002**, *106*, 996-1004.
- [6] Strobel, G.A. Endophytes as sources of bioactive products. *Microbes Infect.*, **2003**, *5*, 535-544.
- [7] Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.*, **2005**, *22*, 15-61.
- [8] Gunatilaka, A.A.L. Natural products from plant-associated microorganisms: distribution, structural diversity, bioactivity, and implications of their occurrence. *J. Nat. Prod.*, **2006**, *69*, 509-526.
- [9] Krohn, K.; Michel, A.; Flörke, U.; Aust, H.-G.; Draeger, S.; Draeger, S.; Schulz, B. Palmarumycins C₁-C₁₆ from *Coniothyrium* sp.: isolation, structure elucidation, and biological activity. *Liebigs Ann. Chem.*, **1994**, *11*, 1099-1108.
- [10] Weber, H.A.; Baenziger, N.C.; Gloer, J.B. Structure of preussomerin A: an unusual new antifungal metabolite from the coprophilous fungus *Preussia isomera*. *J. Am. Chem. Soc.*, **1990**, *112*, 6718-6719.
- [11] Seephonkai, P.; Isaka, M.; Kittakoop, P.; Palittapongarnpim, P.; Kamchonwongpaisan, S.; Tanticharoen, M.; Thebtaranonth, Y. Evaluation of antimycobacterial, antiplasmodial and cytotoxic activities of preussomerins isolated from the lichenicolous fungus *Microsphaeropsis* sp. BCC 3050. *Planta Med.*, **2002**, *68*, 45-48.
- [12] Dong, J.Y.; Song, H.C.; Li, J.H.; Tang, Y.S.; Sun, R.; Wang, L.; Zhou, Y.P.; Wang, L.M.; Shen, K.Z.; Wang, C.R.; Zhang, K.Q. Ymf 1029A-E, preussomerin analogues from the fresh-waterderived fungus YMF 1.01029. *J. Nat. Prod.*, **2008**, *71*, 952-956.
- [13] Martinez-Luis, S.; Della-Togna, G.; Coley, P.D.; Kursar, T.A.; Gerwick, W.H.; Cubilla-Rios, L. Antileishmanial constituents of

the Panamanian endophytic fungus *Edenia* sp.. *J. Nat. Prod.*, **2008**, *71*, 2011-2014.

- [14] McDonald, L.A.; Abbanat, D.R.; Barbieri, L.R.; Bernan, V.S.; Discafani, C.M.; Greenstein, M.; Janota, K.; Korshalla, J.D.; Lassota, P.; Tischler, M.; Carter, G.T. Spiroxins, DNA cleaving antitumor antibiotics from a marine-derived fungus. *Tetrahedron Lett.*, **1999**, *40*, 2489-2492.
- [15] Singh, S.B.; Zink, D.L.; Liesch, J.M.; Ball, R.G.; Goetz, M.A.; Bolessa, E.A.; Giacobbe, R.A.; Silverman, K.C.; Bills, G.F.; Pelaez, F.; Cascales, C.; Gibbs, J.B.; Lingham, R.B. Preussomerins and deoxypreussomerins: novel inhibitors of ras farnesyl-protein transferase. *J. Org. Chem.*, **1994**, *59*, 6296-6302.
- [16] Sakemi, S.; Inagaki, T.; Kaneda, K.; Hirai, H.; Iwata, E.; Sakakibara, T.; Yamauchi, Y.; Norcia, M.; Wondrack, L.M.; Sutcliffe, J.A.; Kojima, N. CJ-12,371 and CJ-12,372, two novel DNA gyrase inhibitors: Fermentation, isolation, structural elucidation and biological activities. *J. Antibiot.*, **1995**, *48*, 134-142.
- [17] Chu, M.; Truumees, I.; Patel, M.; Blood, C.; Das, P.R.; Puar, M.S. Sch 50673 and Sch 50676, two novel anti-tumor fungal metabolites. *J. Antibiot.*, **1995**, *48*, 329-331.
- [18] Wipf, P.; Hopkins, T.D.; Jung, J.-K.; Rodriguez, S.; Birmingham, A.; Southwick, E.C.; Lazo, J.S.; Powis, G. New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. *Bioorg. Med. Chem. Lett.*, **2001**, *11*, 2637-2641.
- [19] Cox, A.D.; Der, C.J. Farnesyltransferase inhibitors: promises and realities. *Curr. Opin. Pharmacol.*, **2002**, *2*, 388-393.
- [20] Leonard, D.M. Ras farnesyltransferase: a new therapeutic target. *J. Med. Chem.*, **1997**, *40*, 2971-2990.
- [21] Kohl, N.E.; Mosser, S.D.; deSolms, S.J.; Giuliani, E.A.; Pompliano, D.L.; Graham, S.L.; Smith, R.L.; Scolnick, E.M.; Oliff, A.; Gibbs, J.B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. *Science*, **1993**, *260*, 1934-1937.
- [22] Macías-Rubalcava, M.L.; Hernández-Bautista, B.E.; Jiménez-Estrada, M.; González, M.C.; Glenn, A.E.; Hanlin, R.T.; Hernández-Ortega, S.; Saucedo-García, A.; Muria-González, J.M.; Anaya, A.L. Naphthoquinone spiroketal with allelochemical activity from the newly discovered endophytic fungus *Edenia gomezpompae*. *Phytochemistry*, **2008**, *69*, 1185-1196.
- [23] Dong, J.Y.; Song, H.C.; Li, J.H.; Wang, C.R.; Sun, R.; Tang, Y.S.; Shen, K.Z.; Wang, L.; Wang, L.M.; Zhou, Y.P.; Li, L.; Zhang, K.Q. Two unusual naphthalene-containing compounds from a freshwater fungus YMF 1.01029. *Chem. Biodivers.*, **2009**, *6*, 569- 577.
- [24] Polishook, J.D.; Dombrowski, A.W.; Tsou, N.N.; Salituro, G.M.; Curotto, J.E. Preussomerin D from the endophyte *Hormonema dematioides*. *Mycologia*, **1993**, *85*, 62-64.
- [25] Soman, A.G.; Gloer, J.B.; Koster, B.; Malloch, D. Sporovexins A-C and a new preussomerin analog: antibacterial and antifungal metabolites from the coprophilous fungus *Sporormiella vexans*. *J. Nat. Prod.*, **1999**, *62*, 659-661.
- [26] Krohn, K.; Florke, U.; John, M.; Root, N.; Steingrover, K.; Aust, H.-J.; Draeger, S.; Schulz, B.; Antus, S.; Simonyi, M.; Zsila, F. New preussomerins J, K and L from an endophytic fungus: structure elucidation, crystal structure analysis and determination absolute configuration by CD calculations. *Tetrahedron*, **2001**, *57*, 4343-4348.
- [27] Krohn, K.; Michel, A.; Flörke, U.; Aust, H.-J.; Draeger, S.; Schulz, B. Palmarumycins CP1-CP4 from *Coniothyrium palmarum*:isolation, structure elucidation, and biological activity. *Liebigs Ann. Chem.*, **1994**, *11*, 1093-1097.
- [28] Schlingmann, G.; West, R.R.; Milne, L.; Pearce, C.J.; Carter, G.T. Diepoxins, novel fungal metabolites with antibiotic activity. *Tetrahedron Lett.*, **1993**, *34*, 7225-7228.
- [29] Chu, M.; Patel, M.G.; Pai, J.-K.; Das, P.R.; Puar, M.S. SCH 53823 and SCH 53825, novel fungal metabolites with phospholipase D inhibitory activity. *Bioorg. Med. Chem. Lett.*, **1996**, *6*, 579-584.
- [30] King, I.; Blood, C.; Chu, M.; Patel, M.; Liu, M.; Li, Z.; Robertson, N.; Maxwell, E.; Catino, J.J. Anti-tumor effect of keto-diepoxides isolated from the fungus *Nattrassia mangiferae*. *Oncol. Res.*, **1995**, *7*, 1-5.
- [31] Powis, G.; Wipf, P.; Lynch, S.M.; Birmingham, A.; Kirkpatrick, D.L. Molecular pharmacology and anti-tumor activity of palmarumycin-based inhibitors of thioredoxin reductase. *Mol. Cancer Ther.*, **2006**, *5*, 630-636.
- [32] Chu, M.; Truumees, I.; Patel, M.G.; Gullo, V.P.; Blood, C.; King, I.; Pai, J.K.; Puar, M.S. A novel class of anti-tumor metabolites from the fungus *Nattrassia mangiferae*. *Tetrahedron Lett.*, **1994**, *35*,1343-1346.
- [33] Thiergardt, R.; Hug, P.; Rihs, G.; Peter, H.H. Cladospirone bisepoxide - a novel fungal metabolite structure determination. *Tetrahedron Lett.*, **1994**, *35*, 1043-1046.
- [34] Thiergardt, R.; Rihs, G.; Hug, P.; Peter, H.H. Cladospirone bisepoxide: definite structure assignment including absolute configuration and selective chemical transformations. *Tetrahedron*, **1995**, *51*, 733-742.
- [35] Petersen, F.; Moerker, T.; Vanzanella, F.; Peter, H.H. Production of cladospirone bisepoxide, a new fungal metabolite. *J. Antibiot.*, **1994**, *47*, 1098-1103.
- [36] Chu, M.; Truumees, I.; Patel, M.G.; Gullo, V.P.; Puar, M.S.; McPhail, A.T. Structure of Sch 49209: A novel anti-tumor agent from the fungus *Nattrassia mangiferae*. *J. Org. Chem.*, **1994**, *59***,** 1222-1223.
- [37] Chu, M.; Truumees, I.; Patel, M.G.; Gullo, V.P.; Pai, J.K.; Das, P.R.; Puar, M.S. Two new phospholipase D inhibitors, SCH 49211 and SCH 49212, produced by the fungus *Nattrassia mangiferae*. *Bioorg. Med. Chem. Lett.*, **1994**, *4*, 1539-1542.
- [38] Bode, H.B.; Walker, M.; Zeeck, A. Secondary metabolites by chemical screening, 42. Cladospirones B to I from *Sphaeropsidales* sp. F-24'707 by variation of culture conditions. *Eur. J. Org. Chem.*, **2000**, 3185-3193.
- [39] Cai, X.; Shan, T.; Li, P.; Huang, Y.; Xu, L.; Zhou, L.; Wang, M.; Jiang, W. Spirobisnaphthalenes from the endophytic fungus Dzf12 of *Dioscorea zingiberensis* and their antimicrobial activities. *Nat. Prod. Commun.*, **2009**, *4*, 1469-1472.
- [40] Jiao, P.; Swenson, D.C.; Gloer, J.B.; Campbell, J.; Shearer, C.A. Decaspirones A-E, bioactive spirodioxynaphthalenes from the freshwater aquatic fungus *Decaisnella thyridioides*. *J. Nat. Prod.*, **2006**, *69*, 1667-1671.
- [41] Hu, H.; Guo, H.; Li, E.; Liu, X.; Zhou, Y.; Che, Y. Decaspirones F-I, bioactive secondary metabolites from the saprophytic fungus *Helicoma viridis*. *J. Nat. Prod.*, **2006**, *69*, 1672-1675**.**
- [42] Dai, J.; Krohn, K.; Elsisser, B.; Floke, U.; Draeger, S.; Schulz, B.; Pescitelli, G.; Salvadori, P.; Antus, S.; Kurtain, T. Metabolic products of the endophytic fungus *Microsphaeropsis* sp. from *Larix decidua*. *Eur. J. Org. Chem.*, **2007**, 4845-4854.
- [43] Chen, X.; Shi, Q.; Lin, G.; Guo, S.; Yang, J. Spirobisnaphthalene analogues from the endophytic fungus *Preussia* sp. *J. Nat. Prod.*, **2009**, *72*, 1712-1715.
- [44] Pai, J.K.; Frank, E.A.; Blood, C.; Chu, M. Novel ketoepoxides block phospholipase D activation and tumor cell invasion. *Anticancer Drug Des.*, **1994**, *9*, 363-372.
- [45] Schlingmann, G.; Matile, S.; Berova, N.; Nakanishi, K.; Carter, G.T. Absolute stereochemistry of the diepoxins. *Tetrahedron*, **1996**, *52*, 435-446.
- [46] Krohn, K.; Beckmann, K.; Floerke, U.; Aust, H.-J.; Draeger, S.; Schulz, B.; Busemann, S.; Bringmann, G. New palmarumycins CP4a and CP5 from *Coniothyrium palmarum*: structure elucidation, crystal structure analysis and determination of the absolute configuration by CD calculations. *Tetrahedron*, **1997**, *53*, 3101-3110.
- [47] Bode, H.B.; Wegner, B.; Zeeck, A. Biosynthesis of cladospirone bisepoxide, a member of the spirobisnaphthalene family. *J. Antibiot.*, **2000**, *53*, 153-157.
- [48] Van der Sar, S.A.; Lang, G.; Mitova, M.I.; Blunt, J.W.; Cole, A.L.; Cummings, N.; Ellis, G.; Munro, M.H.G. Biosynthesis of spiromamakone A, a structurally unprecedented fungal metabolite. *J. Org. Chem.*, **2008**, *73*, 8635-8638.
- [49] Bode, H.B.; Zeeck, A. UV mutagenesis and enzyme inhibitors as tools to elucidate the late biosynthesis of the spirobisnaphthalenes. *Phytochemistry*, **2000**, *55*, 311-316.
- [50] Krohn, K.; Beckmann, K.; Aust, H.-J.; Draeger, S.; Schulz, B.; Busemann, S.; Bringmann, G. Generation of the palmarumycin spiroacetal framework by oxidative cyclization of an open chain metabolite from *Coniothyrium palmarum*. *Liebigs Ann./Recueil*, **1997**, 2531-2534.
- [51] Wipf, P.; Jung, J.-K. Long-range electrostatic effects in synthesis: dipole-controlled nucleophilic addition to a naphthoquinone acetal in model studies toward diepoxin. *Angew. Chem. Int. Ed. Engl.*, **1997**, *36*, 764-767.
- [52] Wipf, P.; Jung, J.-K. Total synthesis of palmarumycin CP1 and (\pm) deoxypreussomerin A. *J. Org. Chem.*, **1998**, *63*, 3530-3531.
- [53] Wipf, P.; Jung, J.-K. Total synthesis of the spiroketal naphthoquinone (±)-diepoxin . *J. Org. Chem.*, **1999**, *64*, 1092-1093.
- [54] Wipf, P.; Jung, J.-K. Formal total synthesis of $(+)$ -diepoxin σ . *J. Org. Chem.*, **2000**, *65*, 6319-6337.
- [55] Wipf, P.; Jung, J.-K.; Rodriguez, S.; Lazo, J.S. Synthesis and biological evaluation of deoxypreussomerin A and palmarumycin $CP₁$ and related naphthoquinone spiroketals. *Tetrahedron*, **2001**, *57*, 283-296.
- [56] Wipf, P.; Lynch, S.M. Synthesis of highly oxygenated dinaphthyl ethers *via* S_NAr reactions promoted by Barton's base. Org. Lett., **2003**, *5*, 1155-1158.
- [57] Wipf, P.; Lynch, S.M.; Birmingham, A.; Tamayo, G.; Jimenez, A.; Campos, N.; Powis, G. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system. *Org. Biomol. Chem.*, **2004**, *2*, 1651-1658.
- [58] Ragot, J.P.; Alcaraz, M.-L.; Taylor, R.J.K. Syntheses of palmarumycin CP₁ and CP₂, CJ-12,371 and novel analogs. *Tetrahedron Lett.*, **1998**, *39*, 4921-4924.
- [59] Ragot, J.P.; Steeneck, C.; Alcaraz, M.-L.; Taylor, R.J.K. The synthesis of 1,8-dihydroxynaphthalene-derived natural products: palmarumycin CP₁, palmarumycin CP₂, palmarumycin C₁₁, CJ-12,371, deoxypreussomerin A and novel analogs. *J. Chem. Soc., Perkin Trans. 1*, **1999**, 1073-1082.
- [60] Ragot, J.P.; Prime, M.E.; Archibald, S.J.; Taylor, R.J.K. A novel route to preussomerins *via* 2-aryacetal anions. *Org. Lett.*, **2000**, *2*, 1613-1616.
- [61] Barrett, A.G.M.; Hamprecht, D.; Meyer, T. Total syntheses of palmarumycins CP_1 and CP_2 and $CI-12,371$: novel spiro-ketal fungal metabolites. *Chem. Commun.*, **1998**, 809-810.
- [62] Barrett, A.G.M.; Blaney, F.; Campbell, A.D.; Hamprecht, D.; Meyer, T.; White, A.J.P.; Witty, D.; Williams, D.J. Unified route to the palmarumycin and preussomerin natural products. enantioselective synthesis of (-)-preussomerin G. *J. Org. Chem.*, **2002**, *67*, 2735-2750.
- [63] Catino, A.J.; Nichols, J.M.; Choi, H.; Gottipamula, S.; Doyle, M.P. Benzylic oxidation catalyzed by dirhodium (II, III) caprolactamate. *Org. Lett.*, **2005**, *7*, 5167-5170.
- [64] Coutts, I.G.C.; Allcock, R.W.; Scheeren, H.W. Novel synthetic approaches to the palmarumycin skeleton. *Tetrahedron Lett.*, **2000**, *41*, 9105-9107.
- [65] Inoue, M.; Nabatame, K.; Hirama, M. A novel route to 1,8 dihydroxynaphthalene-derived natural products. synthesis of (±)- CJ-12,372. *Heterocycles*, **2003**, *59*, 87-92.
- [66] Chi, S.; Heathcock, C. Total syntheses of (±)-preussomerins G and I. *Org. Lett.*, **1999**, *1*, 3-5.
- [67] Quesada, E.; Stockley, M.; Ragot, J.P.; Prime, M.E.; Whitwood, A.C.; Taylor, R.J.K. A versatile, non-biomimetic route to the preussomerins: syntheses of (±)-preussomerins F, K and L. *Org. Biomol. Chem.*, **2004**, *2*, 2483-2495.
- [68] Ouesada, E.; Stockley, M.; Taylor, R.J.K. The first total syntheses of (±)-preussomerins K and L using 2-arylacetal anion technology. *Tetrahedron Lett.*, **2004**, *45*, 4877-4881.
- [69] Miyashita, K.; Sakai, T.; Imanishi, T. Total synthesis of (±) spiroxin C. *Org. Lett.*, **2003**, *5*, 2683-2686**.**
- [70] Miyashita, K.; Imanishi, T. Syntheses of natural products having an epoxyquinone structure. *Chem. Rev.*, **2005**, *105*, 4515-4536.
- [71] Nabatame, K.; Hirama, M.; Inoue, M. A simple desymmetrization approach to the spiroxin framework. *Heterocycles*, **2008**, *76*, 1011- 1016.
- [72] Weerapreeyakul, N.; Anorach, R.; Khuansawad, T.; Yenjai, C.; Isaka, M. Synthesis of bioreductive esters from fungal compounds. *Chem Pharm. Bull.*, **2007**, *55*, 930-935.
- [73] Bringmann, G.; Busemann, S.; Krohn, K.; Beckmann, K. Quantumchemical calculation of CD spectra: the absolute configuration of palmarumycins CP₃ and C₂. *Tetrahedron*, **1997**, 53, 1655-1664.
- [74] Krohn, K.; Steingrover, K.; Zsila, F. The absolute configuration of the palmarumycins C_9 , C_{10} , and C_{12} by quantum-mechanical calculations of CD spectra. *Tetrahedron-Asymmetr.*, **2001**, *12,* 1961- 1964.
- [75] Wang, T.; Shirota, O.; Nakanishi, K.; Berova, N.; McDonald, L.A.; Barbieri, L.R.; Carter, G.T. Absolute stereochemistry of the spiroxins. *Can. J. Chem.*, **2001**, *79*, 1786-1791.
- [76] Ravindranath, N.; Reddy, M.R.; Mahender, G.; Ramu, R.; Kumar, K.R.; Das, B. Deoxypreussomerins from *Jatropha curcas*: are they also plant metabolites. *Phytochemistry*, **2004**, *65*, 2387-2390.
- [77] Kouam; Mpondo, T.N.; Lavaud, C.; Massiot, G.; Nuzillard, J.M.; Connolly, J.D.; Rycroft, D.S. Bipendensin, an unusual phenolic acetal from *Afzelia bipendensis*. *Nat. Prod. Lett.*, **1993**, *3*, 299-303.
- [78] Prajoubklang, A.; Sirithunyalug, B.; Charoenchai, P.; Suvannakad, R.; Sriubolmas, N.; Piyamongkol, S.; Kongsaeree, P.; Kittakoop, P. Bioactive deoxypreussomerins and dimeric naphthoquinones from *Diospyros ehretioides* fruits: deoxypreussomerins may not be plant metabolites but may be from fungal epiphytes or endophytes. *Chem. Biodivers.*, **2005**, 1358-1367.
- [79] Mallavadhani, U.V.; Panda, A.K.; Rao, Y.R. Pharmacology and chemotaxonomy of diospyros. *Phytochemistry*, **1998**, *49*, 901-905.
- [80] Griffin, W.J.; Lin, G.D. Chemotaxonomy and geographical distribution of tropane alkaloids. *Phytochemistry*, **2000**, *53*, 623-637.

Received: April 10, 2010 Revised: June 13, 2010 Revised: June 16, 2010 Accepted: June 16, 2010

- [81] Jensen, S.R.; Franzyk, H.; Wallander, E. Chemotaxonomy of the Oleaceae: iridoids as taxonomic markers. *Phytochemistry*, **2002**, *60*, 213-231.
- [82] Lukaseder, B.; Vajrodaya, S.; Hehenberger, T.; Seger, C.; Nagl, M.; Lutz-Kutschera, G.; Robien, W.; Greger, H.; Hofer, O. Prenylated flavanones and flavanonols as chemical markers in *Glycosmis* species (Rutaceae). *Phytochemistry*, **2009**, *70*, 1030-1037.
- [83] Vilella, D.; Sanchez, M.; Platas, G.; Salazar, O.; Genilloud, O.; Royo, I.; Cascales, C.; Martin, I.; Diez, T.; Silverman, K.C.; Lingham, R.B.; Singh, S.B.; Jayasuriya, H.; Pelaez, F. Inhibitors of farnesylation of Ras from a microbial natural products screening program. *J. Ind. Microbiol. Biotechnol.*, **2000**, *25*, 315-327.
- [84] Okunade, A.L.; Elvin-Lewis, M.P.F.; Lewis, W.H. Natural antimycobacterial metabolites: current status. *Phytochemistry*, **2004**, *65*, 1017-1032.
- [85] Cragg, G.M.; Grothaus, P.G.; Newman, D.J. Impact of natural products on developing new anti-cancer agents. *Chem. Rev.*, **2009**, *109*, 3012-3043.